Ares Financial Consulting
COGT icon

Ares Financial Consulting’s Cogent Biosciences COGT Stock Holding History

Ares Financial Consulting’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-18
Closed -$697 – 1085
2026
Q2 		$697 Buy
+18
New +$630 ﹤0.01% 1056

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Ares Financial Consulting's COGT Position: Q3 2026 in Review

Ares Financial Consulting sold out of Cogent Biosciences (COGT) in Q3 2026, closing a stake of 18 shares — an estimated $697 sold.

Ares Financial Consulting first reported a position in COGT in Q2 2026 and held it in 1 quarter. The position peaked at $697 in Q2 2026. 202 funds tracked by Wall St. Rank hold COGT as of Q3 2026.

  • Ares Financial Consulting reported no remaining Cogent Biosciences position as of Q3 2026 after selling out during the quarter.
  • Ares Financial Consulting sold 18 Cogent Biosciences shares in Q3 2026, an estimated $697.
  • Ares Financial Consulting first reported a position in Cogent Biosciences in Q2 2026 and held it in 1 quarter.
  • Ares Financial Consulting's Cogent Biosciences position peaked at $697 in Q2 2026.
  • 202 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.